← Back to Screener
Edesa Biotech, Inc. Common Shares (EDSA)
Price$6.75
Favorite Metrics
Price vs S&P 500 (26W)129.41%
Price vs S&P 500 (4W)-28.81%
Market Capitalization$49.50M
All Metrics
Book Value / Share (Quarterly)$1.67
P/TBV (Annual)1.66x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.95
Price vs S&P 500 (YTD)313.47%
Gross Margin (TTM)94.65%
Net Profit Margin (TTM)-1935.58%
EPS (TTM)$-1.15
10-Day Avg Trading Volume0.22M
EPS Excl Extra (TTM)$-1.15
EPS (Annual)$-1.93
ROI (Annual)-311.46%
Gross Margin (Annual)94.65%
Net Profit Margin (5Y Avg)-1517.63%
Cash / Share (Quarterly)$1.45
ROA (Last FY)-161.78%
EBITD / Share (TTM)$-1.12
ROE (5Y Avg)-157.84%
Operating Margin (TTM)-1946.75%
Cash Flow / Share (Annual)$-1.03
P/B Ratio3.55x
P/B Ratio (Quarterly)0.85x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)113.91x
Net Interest Coverage (TTM)-7021.32x
ROA (TTM)-52.54%
EPS Incl Extra (Annual)$-1.93
Current Ratio (Annual)10.67x
Quick Ratio (Quarterly)16.51x
3-Month Avg Trading Volume3.00M
52-Week Price Return153.42%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.44
P/S Ratio (Annual)150.56x
Asset Turnover (Annual)0.03x
52-Week High$9.37
Operating Margin (5Y Avg)-1541.38%
EPS Excl Extra (Annual)$-1.93
Tangible BV CAGR (5Y)6.34%
26-Week Price Return138.15%
Quick Ratio (Annual)10.60x
13-Week Price Return308.97%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)16.82x
Enterprise Value$37.453
Asset Turnover (TTM)0.04x
Book Value / Share Growth (5Y)-23.44%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)3.05x
Pretax Margin (Annual)-1935.34%
Cash / Share (Annual)$1.51
3-Month Return Std Dev310.33%
Gross Margin (5Y Avg)-12.60%
Net Income / Employee (TTM)$-0
ROE (Last FY)-311.46%
Net Interest Coverage (Annual)-168.89x
EPS Basic Excl Extra (Annual)$-1.93
Receivables Turnover (TTM)0.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.15
Receivables Turnover (Annual)0.00x
ROI (TTM)-55.75%
P/S Ratio (TTM)150.56x
Pretax Margin (5Y Avg)-1517.32%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.47
Price vs S&P 500 (52W)118.32%
Year-to-Date Return317.61%
5-Day Price Return0.51%
EPS Normalized (Annual)$-1.93
ROA (5Y Avg)-111.64%
Net Profit Margin (Annual)-1935.58%
Month-to-Date Return13.38%
Cash Flow / Share (TTM)$-3.45
EBITD / Share (Annual)$-1.91
Operating Margin (Annual)-1946.72%
ROI (5Y Avg)-157.84%
EPS Basic Excl Extra (TTM)$-1.15
P/TBV (Quarterly)0.99x
P/B Ratio (Annual)1.40x
Inventory Turnover (TTM)1.83x
Pretax Margin (TTM)-1935.34%
Book Value / Share (Annual)$1.74
Price vs S&P 500 (13W)306.10%
Beta-0.60x
Revenue / Share (TTM)$0.00
ROE (TTM)-55.75%
52-Week Low$0.72
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.13
4.13
4.13
4.13
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
EDSAEdesa Biotech, Inc. Common Shares | 150.56x | — | 94.65% | — | $6.75 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Edesa Biotech is a biotechnology company developing therapies for inflammatory and immune-related diseases. Its lead candidate, EB06, is a monoclonal antibody targeting CXCL10 being developed for vitiligo as a potential steroid-sparing treatment option. The company's pipeline includes additional candidates in various stages of development.